A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

Alfonso Quintás-Cardama; Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Francis Giles; Deborah Thomas; William Wierda; Jorge Cortes

doi:10.1080/10428190601075973

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

Identifier:nobleid.org/w1/20260515/6FD338CD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6FD338CD.svg?ark=w1%2F20260515%2F6FD338CD)](https://nobleid.org/work/w1/20260515/6FD338CD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Alfonso Quintás-Cardama

Hagop Kantarjian

Guillermo Garcia-Manero

Claim authorship of this work

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

Identifier:nobleid.org/w1/20260515/6FD338CD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6FD338CD.svg?ark=w1%2F20260515%2F6FD338CD)](https://nobleid.org/work/w1/20260515/6FD338CD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Alfonso Quintás-Cardama

Hagop Kantarjian

Guillermo Garcia-Manero

Claim authorship of this work